MTOR and cancer: The allosteric mTOR inhibitors (e.g., everolimus, temsirolimus, and sirolimus) approved by the Food and Drug Administration (FDA) for human cancers can inhibit mTORC1 but have no obvious inhibiting effect on mTORC2.